|
Fontolizumab
|
DB05111 |
[Fontolizumab (marketed under the trade name HuZAF™) is a humanized monoclonal antibody which is used as an immunosuppressive drug to treat Crohn's disease.] |
|
Flavone
|
DB07776 |
|
|
Cangrelor
|
DB06441 |
[Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset and offset of action. Cangrelor was approved by the FDA in June 2015 for intravenous application.] |
|
VIR201
|
DB05110 |
[ is an experimental therapeutic vaccine currently in clinical trial. The aim of therapeutic vaccines is to augment the body's immune response to HIV and to delay or prevent progression to AIDS.] |
|
Ravuconazole
|
DB06440 |
|
|
FAMOXADONE
|
DB07778 |
|
|
N-({(2S)-1-[(3R)-3-AMINO-4-(2-FLUOROPHENYL)BUTANOYL]PYRROLIDIN-2-YL}METHYL)BENZAMIDE
|
DB07779 |
|
|
Rilapladib
|
DB05119 |
[Rilapladib is the third genomics-derived small molecule drug arising from the Human Genome Sciences-GlaxoSmithKline collaboration to enter clinical development. It is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2 is an enzyme associated with the formation of atherosclerotic plaques.] |
|
R1204
|
DB05118 |
[R1204 is G-protein-coupled receptor modulator. It is developed for the treatment of depression.] |
|
Ilodecakin
|
DB06449 |
|
|
5-(4-FLUOROPHENYL)-3-{[(4-METHYLPHENYL)SULFONYL]AMINO}THIOPHENE-2-CARBOXYLIC ACID
|
DB07770 |
|
|
IGN301
|
DB05117 |
[IGN301 is a cancer vaccine based on an anti-idiotypic antibody which provokes an immune response to Lewis Y. Lewis Y is a carbohydrate molecule expressed on the surface of tumor cells of epithelial origin (e.g. lung, intestinal, breast, prostate or ovarian cancers).] |
|
Lonafarnib
|
DB06448 |
|
|
[(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL]-PHOSPHONIC ACID
|
DB07771 |
|
|
E5531
|
DB06447 |
[E5531 is an endotoxin antagonist.] |
|
Thymectacin
|
DB05116 |
[Thymectacin, a phosphoramidate derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine, is a novel small molecule anticancer agent. Thymectacin is selectively active against tumor cells expressing high levels of thymidylate synthase (TS), a critical enzyme in DNA biosynthesis. Thymectacin was as efficacious as irinotecan, a drug recently approved for the treatment of 5-fluorouracil-resistant colon cancer.] |
|
(1R)-1-{[(4'-methoxy-1,1'-biphenyl-4-yl)sulfonyl]amino}-2-methylpropylphosphonic acid
|
DB07772 |
|
|
NN344
|
DB05115 |
[NN344 is a neutral, soluble long-acting human insulin analogue with 24 hour coverage by once daily injection. NN344 has a very flat and predictable action profile. The product is intended for basal insulin treatment of diabetes mellitus.] |
|
Dotarizine
|
DB06446 |
|
|
5-FLUOROINDOLE PROPANOL PHOSPHATE
|
DB07773 |
|
